Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Over the last decade, the Tec family of nonreceptor tyrosine kinases (Btk, Tec, Bmx, Itk, and Rlk) have been shown to play a key role in inflammation and bone destruction. Bruton's tyrosine kinase (Btk) has been the most widely studied due to the critical role of this kinase in B-cell development and recent evidence showing that blocking Btk signaling is effective in ameliorating lymphoma progression and experimental arthritis. This review will examine the role of TFK in myeloid cell function and the potential of targeting these kinases as a therapeutic intervention in autoimmune disorders such as rheumatoid arthritis.

Original publication

DOI

10.3109/08830185.2012.670334

Type

Journal article

Journal

International reviews of immunology

Publication Date

04/2012

Volume

31

Pages

87 - 103

Addresses

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, University of Oxford, London, UK. nicole.horwood@kennedy.ox.ac.uk

Keywords

Myeloid Cells, Animals, Humans, Mice, Arthritis, Rheumatoid, Autoimmune Diseases, Inflammation, Enzyme Inhibitors, Protein-Tyrosine Kinases